Venus Concept Announces Establishment of Medical Advisory Board For AI.ME™ -Its Next Generation Robotic Platform
July 13 2023 - 7:30AM
Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:
VERO), a global medical aesthetic technology leader, announced
today the establishment of a medical advisory board for AI.ME, its
next generation robotic platform.
The primary mission of the medical advisory
board will be to provide strategic input, guidance, and clinical
recommendations regarding the Company's emerging robotic
technology, AI.ME, which received its first 510(k) clearance from
the U.S. Food and Drug Administration (“FDA”) in December 2022, for
fractional skin resurfacing.
The medical advisory board is composed of six
leading practicing physicians:
Dr. Glynis Ablon, MD, FAAD. – Dr. Ablon is a
board-certified dermatologist and cosmetic surgeon. Dr. Ablon is an
Associate Clinical Professor at UCLA, practicing at both UCLA and
LCMH. She is a Fellow of the American Academy of Dermatology,
American Society for Laser Medicine and Surgery, and American
Society for Dermatologic Surgery. Dr. Ablon is the owner and
medical director of Ablon Skin Institute and Research Center, a
boutique research center, actively performing over 60 clinical
trials.
Dr. Macrene Alexiades, MD, PhD – Dr. Alexiades
is a Fellow of the American Academy of Dermatology and American
Society for Laser Medicine (ASLMS) and Surgery and a Goldman Circle
Member. She has achieved the rare status of Double
Board-Certification in Dermatology in the European Union as well as
the U.S. Dr. Alexiades is also an Associate Clinical Professor,
Yale University and Founder & Director, Dermatology & Laser
Surgery Center of New York.
Dr. Eric Bernstein, MD, MSE – Dr. Bernstein is a
dermatologist and researcher who has published extensively on the
molecular basis of photoaging and the dermatologic uses of
energy-based devices. He holds numerous US and international
patents. Dr. Bernstein is past president of the ASLMS, is a
director for the ASDS, and is Clinical Professor of Dermatology
Perelman School of medicine at the University of Pennsylvania and
Adjunct Professor of Dermatology at Temple University School of
Medicine.
Dr. James Chao, MD, FASC - Dr. Chao is board
certified by the American Board of Plastic Surgery and is a Fellow
of the American College of Surgeons. He is a member of the American
Society of Plastic Surgeons, the American Society for Aesthetic
Plastic Surgery, the American Society of Reconstructive
Microsurgery and was previously the President of the San Diego
Plastic Surgery Society. Dr. Chao serves as plastic and hand
surgeon for the San Diego Chargers professional football team and
is the recipient of numerous prestigious state and national
research awards. In addition, he holds multiple patents of novel
devices for plastic and hand surgery.
Dr. Mitchel Goldman, MD – Dr. Goldman is a past
president of the American Society for Dermatologic Surgery, the
founder and past president of the American College of Phlebology,
and Voted #1 Cosmetic Dermatologist in the USA by Newsweek in 2022
and 2023. He is the director of the American Society for
Dermatologic Surgery Fellowship Program (which he conceived in
2013) and has hospital affiliations with Scripps Memorial Hospital
in La Jolla, California.
Dr. Gilly Munavalli MD, MHS, FACMS – Dr.
Munavalli serves as a Clinical Assistant Professor at the Wake
Forest University School of Medicine – Department of Dermatology
and a Cosmetic Dermatologic Surgery Fellowship Director for the
ASDS. He is founder and owner of Dermatology, Laser, and Vein
Specialists of the Carolinas in Charlotte, NC, where has been in
private practice for almost 20 years.
This diverse team of dermatologists and plastic
surgeons, all of whom have extensive clinical experience in
aesthetic treatments and authored numerous publications in top
peer-reviewed journals, will play an instrumental role in defining
AI.ME's commercialization strategy.
AI.ME is the first and only robotic
system cleared by FDA for fractional skin resurfacing. It uses
machine vision and AI algorithms to target the skin in
a precise, pre-planned, selective, and predictable
manner. It conducts the treatment via a robotic
arm using a smart array of rotating hollow
punches, actuated via smart algorithm, to precisely core and
excise micro skin-tissue fractions, triggering
re-epithelization and collagen deposition.
"We are truly honored to convene this talented
group of industry-leading physicians to form the AI.ME medical
advisory board," said Dr. Hemanth Varghese, President, and Chief
Innovation & Business Officer of Venus Concept. " We believe
that this group of experts is well positioned to guide us in
realizing AI.ME's full clinical potential and ultimately helping us
commercialize AI.ME in a way that transforms patient outcomes and
physicians' approach to aesthetic procedures. We expect to begin
engaging members of this group to start utilizing AI.ME in the
clinical setting in the coming months. We look forward to sharing
more exciting news, as we continue to develop and refine this
technology in anticipation of commercial launch in the second half
of fiscal year 2024."
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 14
direct markets. Venus Concept’s product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Legacy,
Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss,
Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus
Concept’s hair restoration systems include NeoGraft® and the ARTAS
iX® Robotic Hair Restoration system. Venus Concept has been backed
by leading healthcare industry growth equity investors including EW
Healthcare Partners (formerly Essex Woodlands), HealthQuest
Capital, Longitude Capital Management, Aperture Venture Partners,
and Masters Special Situations.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Aug 2023 to Aug 2024